BPC 157
BPC-157 is a synthetic peptide commonly studied in laboratory research related to cell signalling and biochemical processes. It is derived from a naturally occurring protein fragment first explored in gastric research and is now widely used in experimental peptide studies.
BPC 157
Sale!
BPC-157 is a synthetic peptide commonly studied in laboratory research related to cell signalling and biochemical processes. It is derived from a naturally occurring protein fragment first explored in gastric research and is now widely used in experimental peptide studies.
$130.00
Buy more, save more!
-
Save 2%
Buy 3, get $2.50 off each
$130.00Per item: $127.50Total price: $382.50 -
Save 3%
Buy 5, get $3.75 off each
$130.00Per item: $126.25Total price: $631.25 -
Save 6%
Buy 10, get $7.50 off each
$130.00Per item: $122.50Total price: $1,225.00
$150.00$130.00
99+% PURITY
All peptides are third-party lab tested.
SECURE PAYMENT
Your payments are secure with our private security network.
FREE SHIPPING
for orders over $250
Description
Additional information
Reviews (0)
BPC-157 has been observed in research settings to show activity across multiple systems, including muscles, tendons, gastrointestinal tissue, and nervous system models. This broad range of effects makes it useful for comparative studies.
BPC-157 may be involved in several biological processes related to tissue repair. These include promoting angiogenesis, which helps form new blood vessels to improve oxygen and nutrient delivery, and supporting collagen production for structural repair. It has also been linked to cellular migration pathways, such as FAK/paxillin signalling.
Research applications:
- Musculoskeletal models involving tendons, ligaments, and muscle injuries
- Gastrointestinal research focused on ulcers, inflammation, and gut barrier function
- Joint and cartilage studies related to degenerative conditions
- Neurological research in animal models of nerve injury or trauma
- General wound healing studies examining tissue repair mechanisms
There are no reviews yet.